Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.
Julie Collins, MD, MedStar Georgetown University Hospital
Advertisement
Articles by Julie Collins, MD, MedStar Georgetown University Hospital
Advertisement
Latest Updated Articles
Precision Medicine in Metastatic Triple Negative Breast CancerPublished: September 16th 2020 | Updated:
Metastatic HR+ Breast CancerPublished: September 16th 2020 | Updated:
HER2+ Early-Stage Breast Cancer: Peri-Operative TherapyPublished: September 16th 2020 | Updated:
Metastatic HER2+ Breast CancerPublished: September 16th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5